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Introduction
BS is an autosomal dominant monogenic granulomatous
disease due to gain of function mutations at or near the
NACHT domain of NOD2. It is characterized by a triad of
granulomatous polyarthritis, uveitis and rash. Retrospec-
tive work by our group showed a life time risk of ocular
involvement of 60% with significant morbidity and poor
visual outcome. Prospective studies on natural history of
visual outcome are not available. In view of current lack of
effective therapies, research on relevant pathways down-
stream NOD2 is essential and may lead to appropriate
targeted drug development.
Objectives
To study prospectively in detail the phenotype of ocular
involvement and visual outcome in the context of a pro-
spective cohort study on BS. Secondary goals: investigate
possible biomarkers of disease activity and explore relevant
pathways and candidates for therapeutic targeting.
Methods
Participating centers of an ongoing international registry
were invited to enroll patients with NOD2 mutation. IRB
approval was obtained. This 3 year prospective study
consists of one baseline and 3 yearly assessments with a
standardized clinical evaluation, functional assessment,
visual analogue scales, a comprehensive ophthalmologic
assessment and blood sampling for fundamental in vitro
research. Coded data are kept in a secured database at the
coordinating center.
Results
We are reporting baseline ophthalmologic evaluation of
the first 23 patients, virtually a cross section of ocular sta-
tus along disease course. Ages were 0-54 years. 50% 0-15.
More than half had substitutions R334W or R334Q. 19/23
have ocular involvement. Onset of eye disease was
67 months (6-264), 30 months after the onset of arthritis.
Uveitis never preceded joint disease, was bilateral in 90%
and “pan” in 15/19. Despite intense therapy there was
evidence of active disease (+ cells and/or flare for anterior
segment or macular edema) at the time of evaluation in
15/19 patients, (anterior in 8, posterior in 4 and global in
3).For severity assessment in bilateral disease we used the
worse eye. Disease was mild if no local complications
(except cataracts), moderate when complicated and severe
if there was visual loss (WHO). Accordingly 2 were mild,
6 moderate and 11 severe. Corrected visual acuity
(10=100%) was poor, with an average of 7.1 for the right
eye and 6.7 for the left.
Conclusion
Eye involvement in Blau disease is common, severe,
requires intense therapy and lends significant impact on
morbidity. This first prospective cohort multicenter
study of Blau syndrome shows that development of
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